person · Reporting owner

MINOGUE MICHAEL R

Disclosed activity across 2 companies

Tapewire entity: 45352
SEC CIK: 0001286370

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
INSULET CORPPODD · Entity 3516	Director	May 20, 2026	May 21, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

INSULET CORP

Report date May 20, 2026 · Filed May 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,438	Reported balance After 2026-05-20 transaction · row 1 1 source row Row 1 · 2026-05-20 · Grant · Acquired 1,660 · Balance 2,438 F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027.
Common StockSEC Table I · non-derivative	IndirectBy Trust	17,483	Reported balance Holding disclosure · report date 2026-05-20 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 17,483

Filing footnotes · ownership attribution and instrument terms

F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ABIOMED INC

Report date December 22, 2022 · Filed December 27, 2022

Section 16 reporting ended · disclosed 2022-12-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock $.01 par valueSEC Table I · non-derivative	Direct	0	Reported balance After 2022-12-22 transaction · row 1 1 source row Row 1 · 2022-12-22 · Disposition to issuer · Disposed 166,670 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. F3: This number reflects unvested Company RSU Awards and shares of common stock. The Form 4 filed on December 20, 2022 for Michael Minogue inadvertently omitted unvested Company RSU Awards from the balance of non-derivative securities beneficially owned by the reporting person.
Common Stock $.01 par valueSEC Table I · non-derivative	IndirectBy Trust	0	Reported balance After 2022-12-22 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-12-22 · Disposition to issuer · Disposed 243,962 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F3: This number reflects unvested Company RSU Awards and shares of common stock. The Form 4 filed on December 20, 2022 for Michael Minogue inadvertently omitted unvested Company RSU Awards from the balance of non-derivative securities beneficially owned by the reporting person.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.55 · Expires 2024-05-14	Direct	0	Reported balance After 2022-12-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-12-22 · Disposition to issuer · Disposed 85,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.25 · Expires 2025-05-13	Direct	0	Reported balance After 2022-12-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-12-22 · Disposition to issuer · Disposed 35,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.62 · Expires 2026-05-24	Direct	0	Reported balance After 2022-12-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-12-22 · Disposition to issuer · Disposed 30,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $134.51 · Expires 2027-05-15	Direct	0	Reported balance After 2022-12-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-12-22 · Disposition to issuer · Disposed 33,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $381.97 · Expires 2028-05-16	Direct	0	Reported balance After 2022-12-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-12-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $266.39 · Expires 2029-05-30	Direct	0	Reported balance After 2022-12-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-12-22 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $223.90 · Expires 2030-05-29	Direct	0	Reported balance After 2022-12-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-12-22 · Disposition to issuer · Disposed 20,898 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $283.88 · Expires 2031-05-25	Direct	0	Reported balance After 2022-12-22 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-12-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	96,265	Reported balance After 2022-12-22 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-12-22 · Grant · Acquired 96,265 · Balance 96,265 F6: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)).
Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2022-12-22 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-12-22 · Disposition to issuer · Disposed 96,265 · Balance 0 F6: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)).

Filing footnotes · ownership attribution and instrument terms

F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement.

F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share.

F3: This number reflects unvested Company RSU Awards and shares of common stock. The Form 4 filed on December 20, 2022 for Michael Minogue inadvertently omitted unvested Company RSU Awards from the balance of non-derivative securities beneficially owned by the reporting person.

F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option;

F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.

F6: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)

F7: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 09, 2021 Filed Aug 10, 2021 17:07 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	7,037	$350.00	$2,462,950.00	Disclosure SEC source: 0001179110-21-008088 · edgar.xml · nonDerivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,635 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the sale price of the transactions on the reported date at $350.0000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 09, 2021 Filed Aug 10, 2021 17:07 UTC	ABIOMED INC ABMD · Entity 121309	Exercise / conversionCommon Stock $.01 par value	7,037	$23.15	$162,906.55	Disclosure SEC source: 0001179110-21-008088 · edgar.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F5 · shares: Exercise of stock options pursuant to reporting owners 10b5-1 plan. Read SEC document
August 06, 2021 Filed Aug 10, 2021 17:07 UTC	ABIOMED INC ABMD · Entity 121309	Disposition to issuerStock Option (Right to Buy) · Derivative	31,508	$0.00 Strike: $23.15	$0.00	Disclosure SEC source: 0001179110-21-008088 · edgar.xml · derivative · entry 11 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,492 Underlying: Common stock · 31,508 shares Expires 2023-05-14 F2 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan. F8 · date: The exercise of stock options pursuant to the reporting owners 10b5-1 plan occurred over multiple dates. This date represents the earliest exercise reported on this Form. Please refer to Table I for the each of the reported exercise dates. F5 · kind: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F5 · shares: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F1 · derivative.exercise_date: These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6. Read SEC document
August 06, 2021 Filed Aug 10, 2021 17:07 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	24,471	$350.00	$8,564,850.00	Disclosure SEC source: 0001179110-21-008088 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,635 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the sale price of the transactions on the reported date at $350.0000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 06, 2021 Filed Aug 10, 2021 17:07 UTC	ABIOMED INC ABMD · Entity 121309	Exercise / conversionCommon Stock $.01 par value	24,471	$23.15	$566,503.65	Disclosure SEC source: 0001179110-21-008088 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F5 · shares: Exercise of stock options pursuant to reporting owners 10b5-1 plan. Read SEC document
August 05, 2021 Filed Aug 6, 2021 16:16 UTC	ABIOMED INC ABMD · Entity 121309	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $23.15	$0.00	Disclosure SEC source: 0001179110-21-007996 · edgar.xml · derivative · entry 15 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common stock · 25,000 shares Expires 2023-05-14 F2 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan. F5 · kind: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F5 · shares: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F1 · derivative.exercise_date: These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6. Read SEC document
August 05, 2021 Filed Aug 6, 2021 16:16 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	1,000	$344.43	$344,430.00	Disclosure SEC source: 0001179110-21-007996 · edgar.xml · nonDerivative · entry 8 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,635 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F13 · price: This price represents the sale price of the transactions on the reported date at $344.4270. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 05, 2021 Filed Aug 6, 2021 16:16 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	400	$346.08	$138,432.00	Disclosure SEC source: 0001179110-21-007996 · edgar.xml · nonDerivative · entry 7 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,635 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F12 · price: This price represents the sale price of the transactions on the reported date at $346.0750. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 05, 2021 Filed Aug 6, 2021 16:16 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	500	$345.33	$172,665.00	Disclosure SEC source: 0001179110-21-007996 · edgar.xml · nonDerivative · entry 6 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,035 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F11 · price: This price represents the sale price of the transactions on the reported date at $345.3314. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 05, 2021 Filed Aug 6, 2021 16:16 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	1,500	$343.32	$514,980.00	Disclosure SEC source: 0001179110-21-007996 · edgar.xml · nonDerivative · entry 5 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,535 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F10 · price: This price represents the sale price of the transactions on the reported date at $3343.3223. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 05, 2021 Filed Aug 6, 2021 16:16 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	1,335	$342.48	$457,210.80	Disclosure SEC source: 0001179110-21-007996 · edgar.xml · nonDerivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,035 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F9 · price: This price represents the sale price of the transactions on the reported date at $342.4849. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 05, 2021 Filed Aug 6, 2021 16:16 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	5,378	$341.44	$1,836,264.32	Disclosure SEC source: 0001179110-21-007996 · edgar.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,370 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F8 · price: This price represents the sale price of the transactions on the reported date at $341.4448. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 05, 2021 Filed Aug 6, 2021 16:16 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	14,887	$340.27	$5,065,599.49	Disclosure SEC source: 0001179110-21-007996 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,748 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the sale price of the transactions on the reported date at $340.2661. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 05, 2021 Filed Aug 6, 2021 16:16 UTC	ABIOMED INC ABMD · Entity 121309	Exercise / conversionCommon Stock $.01 par value	25,000	$23.15	$578,750.00	Disclosure SEC source: 0001179110-21-007996 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F5 · shares: Exercise of stock options pursuant to reporting owners 10b5-1 plan. Read SEC document
June 21, 2021 Filed Jun 23, 2021 16:05 UTC	ABIOMED INC ABMD · Entity 121309	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $23.15	$0.00	Disclosure SEC source: 0001179110-21-006974 · edgar.xml · derivative · entry 10 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common stock · 25,000 shares Expires 2023-05-14 F2 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan. F5 · kind: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F5 · shares: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F1 · derivative.exercise_date: These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6. Read SEC document
June 21, 2021 Filed Jun 23, 2021 16:05 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	5,343	$326.04	$1,742,031.72	Disclosure SEC source: 0001179110-21-006974 · edgar.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,635 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F8 · price: This price represents the sale price of the transactions on the reported date at $326.0398. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
June 21, 2021 Filed Jun 23, 2021 16:05 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	19,657	$325.16	$6,391,670.12	Disclosure SEC source: 0001179110-21-006974 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,978 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the sale price of the transactions on the reported date at $325.1555. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
June 21, 2021 Filed Jun 23, 2021 16:05 UTC	ABIOMED INC ABMD · Entity 121309	Exercise / conversionCommon Stock $.01 par value	25,000	$23.15	$578,750.00	Disclosure SEC source: 0001179110-21-006974 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F5 · shares: Exercise of stock options pursuant to reporting owners 10b5-1 plan. Read SEC document
May 29, 2021 Filed Jun 2, 2021 16:33 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	1,563	$284.58	$444,798.54	Disclosure SEC source: 0001179110-21-006227 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,635 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
May 27, 2021 Filed May 28, 2021 20:09 UTC	INSULET CORP PODD · Entity 3516	GrantCommon Stock	808	$0.00	$0.00	Disclosure SEC source: 0001127602-21-018311 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,357 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2022 and are settled in shares of common stock on a one-for-one basis. Read SEC document
May 25, 2021 Filed May 27, 2021 16:46 UTC	ABIOMED INC ABMD · Entity 121309	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $283.88	$0.00	Disclosure SEC source: 0001179110-21-006014 · edgar.xml · derivative · entry 16 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-25 F4 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. F3 · derivative.exercise_date: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6. Read SEC document
May 25, 2021 Filed May 27, 2021 16:46 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock $.01 par value	8,503	$0.00	$0.00	Disclosure SEC source: 0001179110-21-006014 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,198 F5 · kind: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 25,2022, May 25, 2023 and May 25, 2024, so long as the reporting person continues to be employed by the issuer on the vesting dates. F5 · shares: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 25,2022, May 25, 2023 and May 25, 2024, so long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document
May 16, 2021 Filed May 18, 2021 17:10 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	4,531	$268.56	$1,216,845.36	Disclosure SEC source: 0001179110-21-005516 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,695 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
May 16, 2021 Filed May 18, 2021 17:10 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	1,627	$268.56	$436,947.12	Disclosure SEC source: 0001179110-21-005516 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,226 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
March 31, 2021 Filed Apr 2, 2021 16:25 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock $.01 par value	52	$0.00	$0.00	Disclosure SEC source: 0001179110-21-004096 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,853 F5 · kind: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). F5 · shares: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). Read SEC document
September 30, 2020 Filed Oct 2, 2020 16:47 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock $.01 par value	55	$0.00	$0.00	Disclosure SEC source: 0001179110-20-010184 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,801 F5 · kind: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). F5 · shares: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). Read SEC document
August 21, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	100	$310.10	$31,010.00	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · nonDerivative · entry 14 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,746 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $304.6400 and $314.8000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 21, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	4,876	$307.96	$1,501,612.96	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · nonDerivative · entry 13 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,846 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $304.6400 and $314.8000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 21, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	11,189	$307.24	$3,437,708.36	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · nonDerivative · entry 12 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,722 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $304.6400 and $314.8000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 21, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	9,235	$306.11	$2,826,925.85	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · nonDerivative · entry 11 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,911 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $304.6400 and $314.8000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 21, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	14,600	$305.20	$4,455,920.00	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · nonDerivative · entry 10 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,146 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $304.6400 and $314.8000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 21, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	Exercise / conversionCommon Stock $.01 par value	40,000	$22.44	$897,600.00	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · nonDerivative · entry 9 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F5 · shares: Exercise of stock options pursuant to reporting owners 10b5-1 plan. Read SEC document
August 20, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	Exercise / conversionStock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $22.44	$0.00	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · derivative · entry 21 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2022-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan. F5 · kind: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F5 · shares: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F1 · derivative.exercise_date: These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6. Read SEC document
August 20, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	2,715	$314.13	$852,862.95	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · nonDerivative · entry 8 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,746 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $304.6400 and $314.8000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 20, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	6,254	$313.23	$1,958,940.42	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · nonDerivative · entry 7 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,461 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $304.6400 and $314.8000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 20, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	5,596	$312.08	$1,746,399.68	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · nonDerivative · entry 6 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,715 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $304.6400 and $314.8000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 20, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	14,196	$311.09	$4,416,233.64	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · nonDerivative · entry 5 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,311 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $304.6400 and $314.8000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 20, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	27,480	$310.09	$8,521,273.20	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · nonDerivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,507 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $304.6400 and $314.8000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 20, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	3,759	$309.40	$1,163,034.60	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,987 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $304.6400 and $314.8000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 20, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	Exercise / conversionCommon Stock $.01 par value	60,000	$22.44	$1,346,400.00	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F5 · shares: Exercise of stock options pursuant to reporting owners 10b5-1 plan. Read SEC document
August 19, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	20,883	$0.00	$0.00	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · nonDerivative · entry 15 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - A Disclosed balance after: 52,555 F8 · kind: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. F8 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. Read SEC document
August 19, 2020 Filed Aug 24, 2020 17:45 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	20,883	$0.00	$0.00	Disclosure SEC source: 0001179110-20-009257 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,746 F8 · kind: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. F8 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. Read SEC document
May 29, 2020 Filed Jun 2, 2020 20:35 UTC	ABIOMED INC ABMD · Entity 121309	GrantStock Option (Right to Buy) · Derivative	20,898	$0.00 Strike: $223.90	$0.00	Disclosure SEC source: 0001179110-20-006838 · edgar.xml · derivative · entry 16 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,898 Underlying: Common Stock · 20,898 shares Expires 2030-05-29 F4 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. F3 · derivative.exercise_date: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6. Read SEC document
May 29, 2020 Filed Jun 2, 2020 20:35 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock $.01 par value	10,567	$0.00	$0.00	Disclosure SEC source: 0001179110-20-006838 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,629 F5 · kind: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 29, 2021, May 29, 2022 and May 29, 2023, so long as the reporting person continues to be employed by the issuer on the vesting dates. F5 · shares: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 29, 2021, May 29, 2022 and May 29, 2023, so long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document
May 28, 2020 Filed Jun 1, 2020 21:00 UTC	INSULET CORP PODD · Entity 3516	GrantCommon Stock	1,029	$0.00	$0.00	Disclosure SEC source: 0001127602-20-018249 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,549 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2021 and are settled in shares of common stock on a one-for-one basis. Read SEC document
May 16, 2020 Filed May 19, 2020 16:32 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	4,546	$184.92	$840,646.32	Disclosure SEC source: 0001179110-20-006306 · edgar.xml · nonDerivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,062 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
May 16, 2020 Filed May 19, 2020 16:32 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	1,632	$184.92	$301,789.44	Disclosure SEC source: 0001179110-20-006306 · edgar.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,608 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
May 15, 2020 Filed May 19, 2020 16:32 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	2,063	$184.27	$380,149.01	Disclosure SEC source: 0001179110-20-006306 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,240 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
May 15, 2020 Filed May 19, 2020 16:32 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	8,506	$184.27	$1,567,400.62	Disclosure SEC source: 0001179110-20-006306 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,303 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
March 31, 2020 Filed Apr 2, 2020 17:11 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock $.01 par value	93	$0.00	$0.00	Disclosure SEC source: 0001179110-20-004525 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,809 F5 · kind: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). F5 · shares: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.